Clinical Trial For Concussion Therapeutic on Recovery Now with Kim Justus
Oxeia CEO Michael Wyand discusses all things brain injury with host Kim Justus including progress with the development of its clinical stage drug. Oxeia is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of mTBI.